Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses
Ngày 18/04/2019 07:15 | Lượt xem: 157

Boston Scientific has announced results from sub-analyses of the IMPERIAL clinical trial for the Eluvia Drug-Eluting Vascular Stent System at the 41st Charing Cross (CX) Symposium (15–18 April, London, UK). Data demonstrated that the efficacy and safety performance of the polymer-coated Eluvia drug-eluting stent does not appear to be affected by challenging lesions, defined as being severely to moderately calcified or completely blocked within the superficial femoral and proximal popliteal arteries.

One of the analyses from the global, randomised controlled IMPERIAL trial, which evaluated the Eluvia drug-eluting stent (DES) in patients with symptomatic peripheral arterial disease, assessed outcomes of patients diagnosed with moderate to severely calcified lesions. Highlights of the findings include:

  • A primary patency rate—a measure of the target vessel remaining unobstructed at 12 months—for patients diagnosed with moderate to severe lesion calcification of 89.2%;[i]
  • A low rate (2.8%) of target lesion revascularisation in study participants with moderate to severe lesion calcification at 12 months;
  • A low rate of stent thrombosis (1.1%) for patients treated with the DES who were diagnosed with moderate to severe lesion calcification.

“Our analysis demonstrated the Eluvia stent is a highly effective treatment option for some of the most complex lesion classifications commonly associated with femoropopliteal disease,” said Frank Vermassen, Ghent University Hospital, Gent, Belgium, an investigator in the IMPERIAL trial who presented the data at CX. “The findings underscore the ability of this stent to successfully treat varying lesion characteristics, and its performance will continue to be observed in ongoing patient follow-up.”

Investigators also analysed the safety and performance of the DES for patients diagnosed with having 100% blockage—or chronic total occlusions—at the target lesion and found that these patients experienced 83.9% primary patency at 12 months.

“The data presented today adds to the clinical evidence supporting the Eluvia Stent System as a viable first-line treatment option for patients suffering from debilitating peripheral artery disease,” said Ian Meredith,  executive vice president and global chief medical officer, Boston Scientific. “Designed with a controlled release of the lowest possible drug dose to seek the best clinical outcomes, we believe the Eluvia stent can become a preferred therapy option and look forward to continued clinical successes with this product.”

The Eluvia Stent System received approval from the US Food and Drug Administration in September of 2018 and CE mark in February of 2016.

Source Vascularnews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua google bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua twitter bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua MySpace bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua LinkedIn bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua stumbleupon bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua icio bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua digg bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua yahoo bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua yahoo bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua yahoo bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses Chia sẽ qua yahoo bài: Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP